Un estudio para investigar la seguridad y tolerabilidad de QEQ278 intravenoso en pacientes con tumores sólidos avanzados
Estudio de fase I/Ib, abierto, multicéntrico, de QEQ278 en pacientes con tumores sólidos avanzados
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.
In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Essen, Alemania, 45147
- Novartis Investigative Site
-
-
-
-
-
Brussels, Bélgica, 1200
- Novartis Investigative Site
-
-
-
-
-
Barcelona, España, 08035
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- University of California LA
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Florida Cancer Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital Dept. of Mass General Hospital
-
-
-
-
-
Paris, Francia, 75231
- Novartis Investigative Site
-
-
-
-
MI
-
Milan, MI, Italia, 20133
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japón, 2778577
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapur, 168583
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwán, 10002
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Adult men and women ≥ 18 years of age.
- Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
- In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
- Non-small cell lung cancer
- Esophageal squamous cell carcinoma
- Renal cell carcinoma
- HPV-associated head and neck squamous cell carcinoma
- Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.
Exclusion Criteria:
- Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
- Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
- Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
- Clinically significant cardiac disease or risk factors at screening
- Insufficient bone marrow function at screening:
- Infections:
- Known history of testing positive for Human Immunodeficiency Virus infection.
- Active Hepatitis B and / or Hepatitis C.
- Active, documented COVID-19 infection
- Known history of tuberculosis
- Any serious uncontrolled infection (acute or chronic).
- Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.
Other protocol-defined inclusion/exclusion criteria may apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Part 1: Dose escalation
Dose escalation with QEQ278 single agent |
Intravenous dosing of QEQ278 |
|
Experimental: Part 2: Dose expansion
Dose expansion with QEQ278 single agent |
Intravenous dosing of QEQ278 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
Periodo de tiempo: 28 days
|
A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT evaluation period and meets the criteria defined in the study protocol. |
28 days
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: Up to 31 months
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs. |
Up to 31 months
|
|
Frequency of dose interruptions, reductions
Periodo de tiempo: Up to 30 months
|
Number of dose interruptions of QEQ278 and number of dose reductions of QEQ278 |
Up to 30 months
|
|
Dose intensity
Periodo de tiempo: Up to 30 months
|
Dose intensity of QEQ278 is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
Up to 30 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall response rate (ORR) per RECIST v1.1
Periodo de tiempo: Up to 30 months
|
ORR is defined as the proportion of patients with a confirmed BOR of complete response (CR) or partial response (PR) by local investigator review as per RECIST v1.1. |
Up to 30 months
|
|
Disease control rate (DCR) per RECIST v1.1
Periodo de tiempo: Up to 30 months
|
DCR is defined as the proportion of patients with a confirmed best overall response (BOR) of CR or PR or stable disease (SD) by local investigator review as per RECIST v1.1. |
Up to 30 months
|
|
Duration of Response (DOR) per RECIST v1.1
Periodo de tiempo: Up to 30 months
|
DOR is defined as the time form the date of the first documented response (CR or PR) to the date of the first documented progression by local investigator review as per RECIST v1.1 or death due to underlying cancer. |
Up to 30 months
|
|
Progression-free survival (PFS) per RECIST v 1.1
Periodo de tiempo: Up to 30 months
|
PFS is defined as the time from the date of start of treatment to the date of the first documented progression by local investigator review as per RECIST v1.1, or death due to any cause. |
Up to 30 months
|
|
Peak serum concentration (Cmax) of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The maximum (peak) serum drug concentration after single dose administration |
During first 168 days of treatment
|
|
Area under the concentration time curve (AUC) last of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The AUC from time zero to the last measurable concentration sampling time |
During first 168 days of treatment
|
|
Area under the concentration time curve (AUC) infinity of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The AUC from time zero to infinity |
During first 168 days of treatment
|
|
Time to reach peak serum concentration (Tmax) of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The time to reach maximum (peak) serum drug concentration after single dose administration |
During first 168 days of treatment
|
|
Elimination half-life (T1/2) of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve |
During first 168 days of treatment
|
|
Total body clearance (CL) of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The total body clearance of drug from the serum |
During first 168 days of treatment
|
|
Volume of distribution (Vz) of QEQ278
Periodo de tiempo: During first 168 days of treatment
|
The apparent volume of distribution during terminal phase |
During first 168 days of treatment
|
|
Incidence of anti-drug antibody (ADA)
Periodo de tiempo: Day 1 and 15
|
Immunogenicity of QEQ278 |
Day 1 and 15
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades pulmonares
- Neoplasias de Cabeza y Cuello
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades esofágicas
- Neoplasias Pulmonares
- Neoplasias Urológicas
- Carcinoma
- Neoplasias De Células Escamosas
- Neoplasias Renales
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Carcinoma De Células Escamosas
- Neoplasias Esofágicas
- Carcinoma de células escamosas de cabeza y cuello
- Carcinoma de células escamosas de esófago
- Carcinoma De Célula Renal
- Carcinoma de pulmón de células no pequeñas
Otros números de identificación del estudio
Otros números de identificación del estudio
- CQEQ278A12101
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .